Document is current
Any future updates will be listed below
-
Authors
Cao, Li
Jia, Ke
Van Tine, BA https://orcid.org/0000-0003-4572-6668
Yu, Yihan
Peng, Yizhong
Chen, Xuanzuo
Pan, Qing
Yang, Wenbo
Zhang, Zhicai
Shao, Zengwu https://orcid.org/0000-0003-1616-8118
Wu, Wei
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82272709, 82072979, 82272709, 82072979, 82272709, 82072979)
- License Information
-
More Information
Article History
Received: 23 September 2024
Revised: 11 March 2025
Accepted: 25 March 2025
First Online: 12 April 2025
Competing interests
: LC, KJ, YY, YP, XC, QP, WY, ZZ, ZS, and WW report no conflicts of interest. VT BA reports research grants from Polaris, Pfizer, Merck, Tracon Pharma, GlaxoSmithKline; consulting fees from Bayer, Cytokinetics Inc., Deciphera Pharmaceuticals, Daiichi Sankyo, EcoR1, Advenchen, Putnam, Salarius Pharmaceuticals, Boxer Capital LLC, Acuta Capital Partners LLC, Aadi Biosciences, Race Oncology Limited, Hinge Bio, Inc., and Kronos Bio, Inc.; honoraria for educational talks from Iteration Therapeutics, Inc. and Total Health Conference; fees for participation in Data/Safety Advisory Boards for Apexigen, Daiichi Sankyo, Epizyme, Bayer, PTC Therapeutics, Aadi Biosciences, Boehringer Ingelheim, Agenus, Regeneron Pharmaceuticals, Advenchen, and Curtis; and speaking fees from Caris, Janssen, Lilly, Target Oncology, Bionest Partners, and Intellisphere LLC.
: The research was carried out in accordance with the principles outlined in the Declaration of Helsinki. The Animal Use and Care Committees at Tongji Medical College, Huazhong University of Science and Technology approved approval for the research (IACUC Number: [2023] 3790).
: All subjects signed a written informed consent.
